# Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia

> **NCT03503318** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 544 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** TV-46000
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03503318
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-27
- **Primary completion:** 2020-09-30
- **Final completion:** 2020-12-03
- **Target enrollment:** 544 (ACTUAL)
- **Last updated:** 2023-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03503318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03503318, "Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03503318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*